KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) FCF Margin (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of FCF Margin data on record, last reported at 44.64% in Q4 2025.

  • For Q4 2025, FCF Margin rose 3762.0% year-over-year to 44.64%; the TTM value through Dec 2025 reached 71.2%, up 6661.0%, while the annual FY2025 figure was 71.2%, 6661.0% up from the prior year.
  • FCF Margin reached 44.64% in Q4 2025 per PACB's latest filing, up from 48.44% in the prior quarter.
  • Across five years, FCF Margin topped out at 44.64% in Q4 2025 and bottomed at 252.99% in Q1 2023.
  • Average FCF Margin over 5 years is 132.13%, with a median of 115.16% recorded in 2023.
  • Peak YoY movement for FCF Margin: crashed -56347bps in 2021, then surged 13725bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 95.92% in 2021, then tumbled by -150bps to 239.35% in 2022, then surged by 57bps to 102.1% in 2023, then increased by 19bps to 82.26% in 2024, then skyrocketed by 46bps to 44.64% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 44.64% in Q4 2025, 48.44% in Q3 2025, and 75.26% in Q2 2025.